Logo image of MNMD

MIND MEDICINE MINDMED INC (MNMD) Stock Fundamental Analysis

NASDAQ:MNMD - Nasdaq - CA60255C8850 - Common Stock - Currency: USD

6.55  -0.19 (-2.82%)

Premarket: 6.63 +0.08 (+1.22%)

Fundamental Rating

2

Taking everything into account, MNMD scores 2 out of 10 in our fundamental rating. MNMD was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of MNMD is average, but there are quite some concerns on its profitability. MNMD has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MNMD had negative earnings in the past year.
In the past year MNMD has reported a negative cash flow from operations.
MNMD had negative earnings in each of the past 5 years.
In the past 5 years MNMD always reported negative operating cash flow.
MNMD Yearly Net Income VS EBIT VS OCF VS FCFMNMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of MNMD (-28.19%) is comparable to the rest of the industry.
MNMD has a Return On Equity (-34.84%) which is in line with its industry peers.
Industry RankSector Rank
ROA -28.19%
ROE -34.84%
ROIC N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
MNMD Yearly ROA, ROE, ROICMNMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MNMD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MNMD Yearly Profit, Operating, Gross MarginsMNMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, MNMD has more shares outstanding
The number of shares outstanding for MNMD has been increased compared to 5 years ago.
MNMD has a better debt/assets ratio than last year.
MNMD Yearly Shares OutstandingMNMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MNMD Yearly Total Debt VS Total AssetsMNMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

MNMD has an Altman-Z score of 2.98. This is not the best score and indicates that MNMD is in the grey zone with still only limited risk for bankruptcy at the moment.
MNMD has a Altman-Z score of 2.98. This is in the better half of the industry: MNMD outperforms 77.44% of its industry peers.
MNMD has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of MNMD (0.10) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 2.98
ROIC/WACCN/A
WACCN/A
MNMD Yearly LT Debt VS Equity VS FCFMNMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 7.27 indicates that MNMD has no problem at all paying its short term obligations.
MNMD has a Current ratio of 7.27. This is in the better half of the industry: MNMD outperforms 78.46% of its industry peers.
A Quick Ratio of 7.27 indicates that MNMD has no problem at all paying its short term obligations.
The Quick ratio of MNMD (7.27) is better than 78.97% of its industry peers.
Industry RankSector Rank
Current Ratio 7.27
Quick Ratio 7.27
MNMD Yearly Current Assets VS Current LiabilitesMNMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

MNMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.84%, which is quite impressive.
EPS 1Y (TTM)58.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.32%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 20.87% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.56%
EPS Next 2Y9.66%
EPS Next 3Y8.81%
EPS Next 5Y20.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MNMD Yearly Revenue VS EstimatesMNMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
MNMD Yearly EPS VS EstimatesMNMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MNMD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNMD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MNMD Price Earnings VS Forward Price EarningsMNMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MNMD Per share dataMNMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.66%
EPS Next 3Y8.81%

More info and screens

0

5. Dividend

5.1 Amount

MNMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIND MEDICINE MINDMED INC

NASDAQ:MNMD (6/27/2025, 8:00:00 PM)

Premarket: 6.63 +0.08 (+1.22%)

6.55

-0.19 (-2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners55.04%
Inst Owner Change37.15%
Ins Owners1.12%
Ins Owner Change16.05%
Market Cap494.85M
Analysts85
Price Target25.76 (293.28%)
Short Float %15.78%
Short Ratio10.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.16%
Min EPS beat(2)-35.89%
Max EPS beat(2)27.56%
EPS beat(4)3
Avg EPS beat(4)4.91%
Min EPS beat(4)-35.89%
Max EPS beat(4)27.56%
EPS beat(8)4
Avg EPS beat(8)-15.12%
EPS beat(12)7
Avg EPS beat(12)-3.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.21%
PT rev (3m)-2.47%
EPS NQ rev (1m)2.96%
EPS NQ rev (3m)4.36%
EPS NY rev (1m)3.18%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.22
P/tB 2.44
EV/EBITDA N/A
EPS(TTM)-1.21
EYN/A
EPS(NY)-1.66
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0
BVpS2.95
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -28.19%
ROE -34.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.75%
ROA(5y)-48.92%
ROE(3y)-68.39%
ROE(5y)-62.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.27
Quick Ratio 7.27
Altman-Z 2.98
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76.32%
EPS Next Y27.56%
EPS Next 2Y9.66%
EPS Next 3Y8.81%
EPS Next 5Y20.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-23.56%
EBIT Next 3Y-10.64%
EBIT Next 5Y29.12%
FCF growth 1Y-81.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-81.72%
OCF growth 3YN/A
OCF growth 5YN/A